Targeting complex solid oral and alternative dosage form generic products

We are committed to expanding our Impax Generics Division by targeting complex solid oral and alternative dosage form Abbreviated New Drug Applications (ANDAs) with high-value, difficult to develop, first-to-file or first-to-market product opportunities, providing certain competitive advantages. In addition to our product pipeline of pending applications at the FDA, we have a number of products in various stages of development for which applications have not yet been filed.